Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ele Ferrannini

Showing results (11-20 of 408) with videos related to

Pageof 41
Sort By:
Diabetes|January 21, 2021
A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement LectureEle Ferrannini
Diabetes Care|September 26, 2015
Of microbes and menEle Ferrannini
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 15, 2010
Sodium-glucose transporter-2 inhibition as an antidiabetic therapyEle Ferrannini
The Lancet. Diabetes & Endocrinology|April 16, 2014
Definition of intervention points in prediabetesEle Ferrannini
Nature Clinical Practice. Endocrinology & Metabolism|December 5, 2006
Keep an eye on diabetesEle Ferrannini
Cell Metabolism|May 17, 2017
Sodium-Glucose Co-transporters and Their Inhibition: Clinical PhysiologyEle Ferrannini
Journal of Hypertension|July 23, 2003
Metabolic effects of antihypertensive treatment: long live the debateEle Ferrannini, Michaela Kozàkovà
Diabetes Care|July 27, 2016
Response to Comment on Rosenstock and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015;38:1638-1642Julio Rosenstock, Ele Ferrannini
Nature Reviews. Endocrinology|October 28, 2017
Therapy: SGLT inhibition in T1DM - definite benefit with manageable riskEle Ferrannini, Anna Solini
Diabetes Care|February 20, 2021
Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?Ele Ferrannini, Julio Rosenstock
Pageof 41

Showing results (11-20 of 408) with videos related to

Sort By:
Pageof 41
Diabetes|January 21, 2021
A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement LectureEle Ferrannini
Diabetes Care|September 26, 2015
Of microbes and menEle Ferrannini
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 15, 2010
Sodium-glucose transporter-2 inhibition as an antidiabetic therapyEle Ferrannini
The Lancet. Diabetes & Endocrinology|April 16, 2014
Definition of intervention points in prediabetesEle Ferrannini
Nature Clinical Practice. Endocrinology & Metabolism|December 5, 2006
Keep an eye on diabetesEle Ferrannini
Cell Metabolism|May 17, 2017
Sodium-Glucose Co-transporters and Their Inhibition: Clinical PhysiologyEle Ferrannini
Journal of Hypertension|July 23, 2003
Metabolic effects of antihypertensive treatment: long live the debateEle Ferrannini, Michaela Kozàkovà
Diabetes Care|July 27, 2016
Response to Comment on Rosenstock and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015;38:1638-1642Julio Rosenstock, Ele Ferrannini
Nature Reviews. Endocrinology|October 28, 2017
Therapy: SGLT inhibition in T1DM - definite benefit with manageable riskEle Ferrannini, Anna Solini
Diabetes Care|February 20, 2021
Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?Ele Ferrannini, Julio Rosenstock
Pageof 41